Hexavalent Vaccine Roll‑out in India’s UIP: Cost‑Benefit Study and Policy Implications

Overview The Union Health Ministry, together with the George Institute for Global Health India , the Gates Foundation, Gavi , and John Snow India, released a study on introducing a hexavalent vaccine into the UIP . The study examined cost, operational efficiency and benefits for children, caregivers and health workers. Key Developments Replacing the current pentavalent and fractional IPV doses with the hexavalent vaccine could cut the number of injections per child. A 50 % reduction in the hexavalent vaccine price would make the savings from reduced logistics, syringes and caregiver time outweigh its higher purchase cost. Two scenarios were modelled: (a) substitution only in the primary schedule, and (b) substitution in both primary and DTP booster schedules. Costs were evaluated from both government and household perspectives, covering procurement, cold‑chain, health‑worker time and caregiver time. Important Facts India vaccinates roughly 26 million infants each year under the UIP. The current regimen requires multiple visits and several injections, increasing the workload of frontline workers and the time burden on families. The hexavalent vaccine, while more expensive per dose, reduces the total number of injections, eases cold‑chain storage, and lowers the need for syringes. Researchers found that the vaccine’s price is the single biggest driver of overall programme cost. If the price falls by half, the operational savings—fewer cold‑chain trips, less staff time, and reduced caregiver travel—become larger than the extra procurement expense. UPSC Relevance This study touches on several GS topics. It illustrates how cold‑chain considerations affect public‑health budgeting, a classic GS‑3 question on health economics. The involvement of international partners like Gavi and the Gates Foundation highlights the